Physician profile
Michael H Wei
NPI 1952385643
$2,069.86
in general payments reported to CMS, 2019-2025
17 companies · $17.38 in 2025
The $17.38 reported for 2025 was less than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $218 · 2020: $181 · 2021: $142 · 2022: $359 · 2023: $367 · 2024: $784 · 2025: $17.38.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $822 · Travel and Lodging: $329 · Education: $17.38.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $822.08 |
| Travel and Lodging | $329.08 |
| Education | $17.38 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medical Device Business Services, INC. | $569.23 | 2024 | Monarch |
| Glaxosmithkline, LLC. | $481.12 | 2019-2024 | Arexvy, Trelegy Ellipta, Nucala |
| Mylan Specialty L.P. | $174.28 | 2020-2024 | Yupelri |
| Insmed, INC. | $147.54 | 2020-2025 | Arikayce, Brinsupri |
| Actelion Pharmaceuticals US, INC. | $124.99 | 2024 | Opsumit, Uptravi |
| United Therapeutics Corporation | $122.79 | 2022 | |
| Outset Medical INC | $109.22 | 2023 | |
| Astrazeneca Pharmaceuticals LP | $95.41 | 2020-2024 | Airsupra |
| Genentech USA, INC. | $71.83 | 2019 | |
| Implant Direct Sybron International LLC | $30.46 | 2019 | |
| Body Vision Medical INC. | $29.22 | 2024 | Lungvision |
| Veran Medical Technologies, INC. | $22.15 | 2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $21.83 | 2022 | |
| Paratek Pharmaceuticals, INC. | $20.42 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $18.98 | 2022 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Csl Behring | $16.62 | 2022 | |
| Merck Sharp & Dohme LLC | $13.77 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Wei listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.